Trump administration’s embattled FDA vaccine chief is leaving again
The Food and Drug Administration is once again facing turmoil as Dr. Vinay Prasad, the agency’s vaccine chief, is set to depart for the second time in less than a year. This news comes after a series of controversial decisions made by Prasad regarding the review of vaccinations and specialty drugs for rare diseases.
FDA Commissioner Marty Makary announced Prasad’s departure in an email to FDA staff, stating that Prasad would be returning to his academic position at the University of California, San Francisco by the end of April. This decision follows Prasad’s previous departure last July, when he clashed with biotech executives, patient groups, and conservative allies of President Donald Trump. Despite being reinstated with the support of Health Secretary Robert F. Kennedy Jr. and Makary, Prasad’s latest exit raises concerns about the agency’s leadership.
Prasad’s recent controversies involve the FDA’s review of vaccines, gene therapies, and biotech drugs, with companies criticizing the agency for reversing decisions and calling for additional trials of previously approved products. One of the most notable incidents was Prasad’s initial refusal to review a flu vaccine from Moderna, made using mRNA technology. After public backlash, the FDA reversed course and accepted the vaccine for review pending additional studies.
In another contentious issue, the FDA clashed with UniQure, a small drug company developing an experimental treatment for Huntington’s Disease. The agency demanded a new trial involving a sham surgery on patients, prompting ethical concerns and criticism from the company. The FDA defended its request for an additional study in a rare press conference, labeling the company’s original study as “stone cold negative.”
Prasad’s tenure at the FDA has been marked by disagreements with drug companies over regulatory decisions, leading to rejections and requests for additional studies that prolong development timelines and increase costs. As a vocal critic of the FDA’s drug review standards, Prasad’s approach to regulation has puzzled many observers. While he has supported measures to expedite drug reviews, he has also imposed new warnings and study requirements, particularly for COVID vaccines, a contentious issue for Kennedy, a known anti-vaccine activist.
The ongoing controversies surrounding Prasad’s leadership raise questions about the FDA’s decision-making process and its impact on public health. As the agency navigates these challenges, stakeholders are closely monitoring the developments to ensure transparent and effective regulatory practices.
